Company news
Phathom Pharmaceuticals, Inc. news in 2022
Phathom Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 7, 2022
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 2, 2022
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
October 31, 2022
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
October 23, 2022
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 22, 2022
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 17, 2022
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
September 25, 2022
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 1, 2022
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 24, 2022
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 23, 2022
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 16, 2022
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 9, 2022
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 3, 2022
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 2, 2022
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
April 25, 2022
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
March 31, 2022
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
March 21, 2022
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 13, 2022
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
February 28, 2022
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
February 8, 2022
Decks in 2022
- Fact Sheet (August 2022)
Fact sheet · 2 slides · August 2022